Safe Software Celebrates Partner of Excellence Award Winners
The Awards Were Presented at the Partner Summit at The Peak of Data and AI in Seattle
Surrey, BC, May 05, 2025 (GLOBE NEWSWIRE) -- Tonight, Safe Software (Safe), the leading all-data, any-AI enterprise integration vendor, announced eight Partner Excellence Award winners. The selected Safe Software ecosystem partners were presented with their awards during the Partner Summit at the company's largest user conference to-date, The Peak of Data and AI, in Seattle, WA.
Safe Software presents the Partner Excellence Award to members of its partner ecosystem that excel in promoting sales excellence, marketing innovation, expansion initiatives, and FME product development efforts.
2025 Partner Excellence Award Winners:
Amazon Web Services: Selected as Safe's Technical Partner of the Year, in recognition for its partnership in providing guidance and introductions for growth in the AWS marketplace and go-to-market activities.
Avineon Tensing UK: Recognized as Safe Software's fastest-growing partner for two consecutive years, owing to its exemplary collaboration across departments and exceptional customer engagement through events, artificial intelligence initiatives, and strategic sales efforts.
con terra: Awarded for its innovative approach to subscriptions, deep technical collaboration, and enthusiastic involvement across various Safe Software FME initiatives, fostering substantial growth and engagement.
Locus Australia: Celebrated for its innovative marketing leadership through its FME Accelerators workshops, achieving the highest growth in the APAC region in FY24, and demonstrating a commitment to enhancing FME expertise and regional influence within Southeast Asia.
Sweco: Honoured for its substantial year-over-year sales growth, having achieved an impressive 36% increase in FY23 and 11% in FY24, as well as for its strategic regional expansion and its integration of FME into consulting services, backed by impactful marketing collaborations.
Consortech: Awarded for steady subscription growth, creative solution selling with Flow Hosted, and active, high-quality collaboration with Safe Software's Sales, Marketing and Training teams.
Globema: Recognized for its standout marketing engagement, dedication to internal FME enablement, and proactive collaboration across various regions to promote subscription readiness.
IMGS: Honoured for its adaptable, industry-centric sales approach, early adoption of AI and solution selling. It achieved a remarkable 62% growth in FY24, driven by strategic expansion within the United Kingdom.
'Our partnership ecosystem spans diverse industries and regions around the world, which is made evident by the winners of tonight's Partner Excellence Awards,' said Don Murray, Co-Founder and CEO of Safe Software. 'Congratulations to all of the award winners, and thank you for continuing to be innovative partners that we at Safe Software depend on to bring even more options to harness the power of data to FME users.'
All award winners are members of Safe Software's global partner ecosystem, which the company has been expanding to include even more organizations across new regions and industries. Over 160 unique partners from around the world help bring diverse expertise and solutions to Safe Software's FME users.
For more information on the company's partner program, please visit: https://fme.safe.com/partners/.
The Peak of Data and AI, which officially begins tomorrow, on May 6th, and runs until Thursday, May 8th. The full agenda can be seen here for more information: https://peakofdataintegration.com/.
END
About Safe SoftwareHeadquartered in Surrey, British Columbia, Safe Software is the creator of FME, the only All-Data, Any-AI enterprise integration platform. The company was founded in 1993 and has been focused on bringing life to data since its inception. Whether your challenges have to do with spatial data, big data, stream processing, cloud migration, or business intelligence, Safe Software is here to help you spend more time reaping the benefits of information, and less time fighting it.
For more information, visit safe.com.
About FME by Safe SoftwareThe FME Platform has built-in support for thousands of systems as well as 800+ out-of-the-box transformers allowing users to build and automate custom integration workflows without having to code. Over 20,000 organizations worldwide trust FME technology for their enterprise integration solutions. Through Safe Software's international partner network, FME is used in 120+ countries around the world and has been localized into multiple languages.
For more information, visit fme.safe.com.
CONTACT: Elan Paris DGPR 778 988 6525 elan.paris@dg-pr.comSign in to access your portfolio
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 days ago
- Yahoo
Fresenius Medical starts US commercialisation of haemodiafiltration system
Fresenius Medical Care (FME) has commenced the US commercialisation of its high-volume haemodiafiltration (HVHDF) kidney replacement therapy, 5008X CAREsystem. The full-scale commercial launch is anticipated by the company in 2026. FME secured the Food and Drug Administration's (FDA) 510(k) clearance last week for the updated HDF-capable system. In February 2024, FME first obtained the clearance for the 5008X CAREsystem, enabling focused testing and clinical assessments. The latest clearance approves additional features, including the Fresenius Clinical Data Exchange (CDX), which facilitates ONE-TOUCH access to medical information systems, eliminating the need for extra computer stations. The CDX claims to optimise clinic workflows, mitigate cross-contamination risks, and reduce citations under the CMS V-tag by streamlining data access and freeing up the clinic area by minimising the cabling clutter. Over the coming months, FMS' Care Delivery patient care business segment will start providing HDF dialysis therapy in chosen first wave clinics within its US Fresenius Kidney Care dialysis clinics network. This gradual rollout will continue throughout the year. The 5008X CAREsystem, paired with the FDA-approved FX CorAL dialyser, represents a leap in medical device innovation by Fresenius. It not only enables HVHDF but also introduces enhancements in workflow and therapy. The CONVINCE study, funded by the EU and conducted across eight European countries, found that subjects undergoing HVHDF had a significant 23% reduction in death rates against those receiving high-flux haemodialysis. FME CEO Helen Giza said: 'Last week's FDA clearance of our updated 5008X CAREsystem with additional features was a critical milestone in our work to improve the lives of people living with kidney disease by bringing industry-leading, HVHDF dialysis therapy to the US. 'Haemodiafiltration is already the treatment standard across much of Europe, Latin America, and Asia, and we are very well experienced with it. Our great familiarity with this treatment, combined with the outcome and promising results of the external CONVINCE research study, reiterated the significant patient health and well-being benefits available with HVHDF.' "Fresenius Medical starts US commercialisation of haemodiafiltration system" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio
Yahoo
3 days ago
- Yahoo
Fresenius Medical starts US commercialisation of haemodiafiltration system
Fresenius Medical Care (FME) has commenced the US commercialisation of its high-volume haemodiafiltration (HVHDF) kidney replacement therapy, 5008X CAREsystem. The full-scale commercial launch is anticipated by the company in 2026. FME secured the Food and Drug Administration's (FDA) 510(k) clearance last week for the updated HDF-capable system. In February 2024, FME first obtained the clearance for the 5008X CAREsystem, enabling focused testing and clinical assessments. The latest clearance approves additional features, including the Fresenius Clinical Data Exchange (CDX), which facilitates ONE-TOUCH access to medical information systems, eliminating the need for extra computer stations. The CDX claims to optimise clinic workflows, mitigate cross-contamination risks, and reduce citations under the CMS V-tag by streamlining data access and freeing up the clinic area by minimising the cabling clutter. Over the coming months, FMS' Care Delivery patient care business segment will start providing HDF dialysis therapy in chosen first wave clinics within its US Fresenius Kidney Care dialysis clinics network. This gradual rollout will continue throughout the year. The 5008X CAREsystem, paired with the FDA-approved FX CorAL dialyser, represents a leap in medical device innovation by Fresenius. It not only enables HVHDF but also introduces enhancements in workflow and therapy. The CONVINCE study, funded by the EU and conducted across eight European countries, found that subjects undergoing HVHDF had a significant 23% reduction in death rates against those receiving high-flux haemodialysis. FME CEO Helen Giza said: 'Last week's FDA clearance of our updated 5008X CAREsystem with additional features was a critical milestone in our work to improve the lives of people living with kidney disease by bringing industry-leading, HVHDF dialysis therapy to the US. 'Haemodiafiltration is already the treatment standard across much of Europe, Latin America, and Asia, and we are very well experienced with it. Our great familiarity with this treatment, combined with the outcome and promising results of the external CONVINCE research study, reiterated the significant patient health and well-being benefits available with HVHDF.' "Fresenius Medical starts US commercialisation of haemodiafiltration system" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Erreur lors de la récupération des données Connectez-vous pour accéder à votre portefeuille Erreur lors de la récupération des données Erreur lors de la récupération des données Erreur lors de la récupération des données Erreur lors de la récupération des données
Yahoo
4 days ago
- Yahoo
Turkey to press allies for access to EU defence funds
By Tuvan Gumrukcu ANKARA (Reuters) - Turkey will press European allies which plan to sharply ramp up their defence spending to ease restrictions that now require most of that money to be spent in the EU, Defence Minister Yasar Guler told Reuters on Wednesday ahead of a NATO meeting. In written answers to questions from Reuters, Guler also said Turkey hopes a potential meeting between Donald Trump and Tayyip Erdogan will finally yield progress in lifting U.S. sanctions that expelled Turkey from the F-35 jet programme. Guler said Turkey, which has the second biggest army in NATO after the United States, has advanced capabilities in areas such as drones, which would be valuable to its allies as they plan major new spending on defence. "Allies need to spend not only more, but also smarter – and there is a need for more cooperation than ever before," Guler said when asked about Trump's call on the alliance to ramp up defence spending to target 5% of output. Many European nations have announced plans for major increases in defence spending. The EU itself, driven by fears of a Russian attack and doubts about U.S. security commitments, has approved creating a 150 billion-euro ($170 billion) EU arms fund to boost the defence industry, labelled the SAFE scheme. But it mandates that 65% of projects are funded by firms in the bloc, the broader European Economic Area, or Ukraine. Guler said such restrictions would exclude non-EU countries like Turkey from Europe's defence and security architecture, which he said was "an issue that cannot be discussed only within the EU". Turkey wants to "build the security of the future together" with the EU, and would continue to work with "open-minded and visionary European allies within or outside SAFE," he said, specifically listing drones, air defences, naval systems, armoured vehicles and land platforms, electronic warfare and radar systems, ammunition and rocket systems. Greece, Turkey's longstanding adversary, has demanded Ankara lift a lift a 30-year old war threat over territorial waters to be permitted to access EU defence funds. Guler said such demands were a mistake, amounting to "involving multilateral platforms in bilateral disputes". Ankara's defence cooperation with its NATO allies has been hampered in recent years by U.S. sanctions imposed over a Turkish decision to buy Russian S-400 air defence systems, which resulted in Turkey's expulsion from the U.S.-led F-35 programme as both a buyer and manufacturer of the advanced jets. Erdogan has expressed confidence that Trump, with whom he has good personal ties, will find a solution that relieves Turkey's defence industry of the sanctions. A potential meeting between Erdogan and Trump, and the close ties between them, can "breathe new life" into bilateral defence ties and help lift the sanctions, Guler said. Although Ankara would not give up the S-400s, lifting the sanctions would let it consider returning to the F-35 project, he said. ($1 = 0.8792 euros) (Writing by Huseyin Hayatsever; Editing by Jonathan Spicer and Peter Graff)
